The European Union is still firm in its proposal to repair medications despite the pressure of industry
he European Executive Union He remains optimistic about the possibility of achieving a positive result through continuous negotiations with legislators in Pharmaceutical framework review From the bloc and you will not make the original proposal despite the requests of the sector mentioned in Europe.
Las Pharmaceutical companies They recently urged the committee to promote protection intellectual property And presenting new incentives to support innovation, especially before Tensions Emerging and the demands of the most suitable conditions.
Companies like French Sanovi And the Swiss giant Novartis I also pressed in a message to reduce Price controlsThe pretext that the current policies make the European Union market less attractive compared to Americans, as it is allowed to high prices.
To amend the current proposal, the committee must formally withdraw it and submit a new copy, because the legislative process is now in the hands of European Parliament The European Union Council. However, the committee has no intention to do so.
A spokesman for the committee said on Wednesday: “In general and theoretical conditions, if the files remain blocked by colleges within a long time and there are no signs of progress, we can think about their withdrawal.” “But this is not the case. We are actively working with Collegislators to achieve a positive decisionHe added.
European pharmacists fear a commercial battle with the United States of America.
Sector pressure is partially due to an imminent trade war with the United States. Although they have not yet been imposed dutyAdministration Trump It has begun an investigation, which is an initial step towards its application. European Union officials have also realized their concern about the possibility of these rates to become a reality.
To exacerbate tension is the reports that arose earlier this week that the US government can try to link Medicine prices From the country to the countries of other developed countries. Pharmaceutical companies are now afraid European prices It remains low, Americans can also be forced, and thus an invitation to raise costs in Europe to deter such maneuvers.
In response to the unfinished commercial environment, many large pharmaceutical companies have announced the importance of Investments in the United States To reduce the effect of any tariff. Novartis recently promised to invest $ 23,000 million (more than 20326 million euros) in American manufacturing, while RushAnd its headquarters in Switzerland, did the same with an investment of $ 50,000 million (about 45,000 million euros).
The committee is still optimistic
Since the proposal to reform in May 2023, discussions have been submitted in the European Parliament, but the movements have almost occurred in the Council. However, the committee maintains hope. “I don’t know that the talks are very poor. We are optimistic about adoption,” the spokesman added.
The most prominent initiatives such as A proposal of the Monetary Medicine Law A recent invitation between the Chairman of the Committee, Ursula von der Lin, and the leaders of the drugs, who opened a Dialogue on industry concerns.
The committee pledged to meet this needs The main industryNot only from an economic point of view, but above all for the health of our citizens, “he said.” We also intend that the European market is more attractive to pharmaceutical innovation and manufacturing, “the committee spokesman added.
